Shandong Xinhua Pharmaceutical Wins NMPA Approval for Phloroglucinol Injection
I'm PortAI, I can summarize articles.
Shandong Xinhua Pharmaceutical Company Limited has received approval from China's National Medical Products Administration for its Phloroglucinol Injection, a drug aimed at treating acute spasmodic pain. This approval allows the company to proceed with commercial production and sales, enhancing its offerings in the pain-management sector. The company, listed in Hong Kong, focuses on developing and selling chemical drugs for the Chinese market and beyond.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments